Qualsiasi forma di Chemio-Terapia causa un danno irreparabile alle condizioni fisiche di coloro che si espongono all’azione di questi veleni, chiamati ”farmaci cito-tossici”.
Lo stesso Giuramento d’Ippocrate fa espressamente divieto di somministrare “veleno” al paziente, anche se richiesto dall’ammalato stesso (vedi Giuramento d’Ippocrate).
Questi veleni (”Farmaci cito-tossici”), entrano nel circolo sanguigno tramite iniezione e/o fleboclisi endovenosa, oppure per assorbimento indiretto dallo stomaco o dalla mucosa intestinale.
Questo tipo di trattamento è diverso dalla Chirurgia o dalla Radio-Terapia, che concentrano i loro effetti su punti o aree specifici the human body (therapy "targeted"). In hospitals
reference is made to chemotherapy when there is the possibility that cancer cells may be present in other areas of the body besides the location of primary tumor. But rarely
chemotherapy provides a survival period of at least 5 years, indicated wrongly as "period of care."
chemo-therapy temporarily stops the abnormal cell growth, or it can relieve pain for some time, or lengthen a short survival time.
Rarely can one speak of "forgiveness" bibliographic data refer percentage of success in less dell1% for cancer pancreas, 3% in case of liver cancer, 7% in case of bowel cancer ... .. There are about 60-70
cytotoxic drugs on the market worldwide. For Italy
trade names are shown in Table 2a (partial list):
Some of these poisons cause fewer problems than others such as insomnia, fatigue, diarrhea, alopecia, stomatitis, leukopenia, thrombocytopenia, anemia, nausea, vomiting ...
These are the immediate side effects and known because visibly detectable.
What they rarely talk about are the effects more severe and longer lasting, the consequences of deeply deteriorate the patient's life and the course of the same his illness, making it useless even therapies based on the immunity-stimulating natural killer cells, apoptotic activity and detoxification of extracts of medical plants.
These profound and irreversible damage, which is rarely discussed, are as follows:
severe reduction, stable and durable, the number of specific types and subtypes of white blood cells essential for the specific immune response against the tumor.
2) somatic cell mutation type, with the appearance of other secondary malignancies and / or metastasis
3) type of germ cell mutations (testes or ovaries), with onset of sterility, abortions or malformed babies in those cases the surviving parent chemo-therapy e al Cancro.
4) accelerazione della crescita del tumore, anzichè una sua riduzione, con comparsa di resistenza crociata del tumore ad altri veleni (pompa glicoproteica di membrana).
La Chemio-Terapia è quindi controindicata in maniera assoluta in qualsiasi forma di associazione alla Immuno-Terapia.
La Chemio-Terapia è infatti gravemente depletoria soprattutto nei confronti dei linfociti, di cui è stata riconosciuta la buona capacità di identificazione e di distruzione di masse tumorali mediante Immuno-Terapia specifica anti-neoplastica .
Si può infatti affermare, secondo l'autore del presente lavoro, che saranno solo e soltanto le difese immunitarie del paziente stesso a risolvere la patologia neoplastica, thus leads to a complete recovery from cancer.
Surgery and radiation therapy should be considered only as a technique or method of support able to eliminate a certain proportion of the primary tumor and its metastases, provided that neither of these components must be considered a cause of end-healing patients from cancer: the possible and actual patient's recovery from his cancer and only depend only on the ability of the immune system to recognize and selectively destroy the tumor and radical immuno-therapy to chemotherapy, therefore, denies any value treatment or cure against cancer.
It can be said that has already been shown in medical literature substantial failure of chemo-therapy for almost all types of cancer chemo-therapy reduces the tumor mass, even for the most serious price to cause widespread damage to all organs and tissues of the patient, resulting in: bone marrow failure (with the consequence of infection and loss of immune defense against tumor), kidney and liver failure, possible changes in pulmonary fibrosis with respiratory failure, heart damage and blood vessels, leukemia and secondary cancers in varying proportions.
In any case, the recovery is almost always cancer, often characterized by cross-resistance of cancer cells to other chemotherapy drugs, in cycles of chemotherapy after second-or third-line, to be defined ultimately in terms of totally inappropriate, "chemotherapy rescue" actually a chemo-therapy and final destruction, carried out with various chemotherapeutic drugs type, which can never save the patient, or even to lead to real healing. ... "The Professor
. Hardin Jones, University of California, demonstrates for the first time in a large-scale study lasted 23 years , which for cancer patients who refused to undergo surgery, radiotherapy and chemotherapy, (but with free food, no special diets), the median survival is 3-4 times more high compared with those who underwent a standard medical treatment (surgery, radiotherapy and chemotherapy).
This finding has been confirmed since then several times in the medical literature, such as breast cancer (1067) [The natural history of breast cancer in the elderly: Implications for screening and treatment, Cancer 2004; 100 (9) , pp. :1807-1813] where in the absence of official medical therapies the median survival of women with breast cancer is 12 and a half years, while those who received standard medical treatment (surgery, radiotherapy and chemotherapy Therapy), died within an average of 3 years.
Given all this, of multicenter trials cliniche su donne affette da cancro al seno, pubblicati nel 2003-2004, in merito agli esiti di combinazioni varie di Chemio-Terapie, riportano esiti totalmente inconcludenti: ad esempio con tempo libero di malattia di circa 5 mesi, e mediana di sopravvivenza di 15 mesi (1068)[Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer, Eur. J.Cancer, 2004; 40(4), PP:536-542], oppure nella cosiddetta “chemio di salvataggio”, con mediane di sopravvivenza libera di soli 8 mesi, con tempo medio di risposta di 4 mesi, e una progressione di malattia entro 5 mesi (1069)[Full dose paclitaxel plus vinorelbine as salvage chemotherapy anthracycline-resistant advanced breast cancer: a phase II study, J.Chemother. 2003,15(6),pp.:607-612], oppure con tempi di sopravvivenza libera da progressione di malattia di 3 anni con mediana di sopravvivenza di circa 1 anno (1070)[Phase II study of docetaxel in combination with epirubicin an protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer.
A Yorkshire breast cancer research group study, Br.J.Cancer, 2004, 90(11),pp.:2131-2134], oppure con mediana di sopravvivenza di 2 anni (1071)[Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study, J.Clin.Oncol.2004,22(12),pp: 2321-2327], oppure con sopravvivenza libera progression of disease 8-10 months, with median survival of 18-19 months (1072) [Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in Patients with advanced breast cancer: a Scandinavian Breast Group Trial, J . Clin.Oncol.2004, 22 (12), pp. :2313-2320]. Finally, the use of "compassionate" of chemotherapy given by mouth: "... An open-label, non randomized, compassionate-use study ... Was Carried" (1073) [Oral capecitabine in anthracycline and taxane-pretreated advanced / metastatic breast cancer, Acta Oncol., 2004.43 (2), pp. :186-189].
Again, in 1990, prof. Ulrich Abel, dell''Università Heidelberg said: "... although the chemotherapy drugs lead to a" response ", ie a decrease in tumor mass, this reduction does not produce a prolongation of survival of the patient, indeed, the cancer returns more aggressively than before, because the chemotherapy promotes the growth of strains resistant tumor. In addition, chemotherapy severely damages the body's defenses, including the immune system, often the kidneys and liver .... "
According to data presented by Dr. Abel, patients treated with chemotherapy were significantly smaller in terms of survival, than patients treated with conventional medicine, grouped and compared to type and stage of cancer.
Abel says: "... fair and balanced analysis of the medical literature shows a success rate close to zero in therapeutic treatments conventionally used to treat advanced forms of solid tumors" ... (Chemothrapy of advanced epithelial cancer: a critical survey. HippokratesVerlag , Stuttgart, 1990; Healing Journal, No.1-2, Vol.7, 1990)
In 1991, the oncologist Albert Braverman writes: "... any type of solid tumor that was considered incurable in 1975 is curable today. Many oncologists recommend chemotherapy for virtually any form of cancer, with expectations that the systematic failure does not deter ... "
When chemotherapy is helpful.
chemo-therapy is useful only in 1.5% (one point five percent) of the cases according to a WHO committee in 1980.
According to a survey of 1,500 scientific publications made by prof. Jones of the University of California, the success rate rises to 2%. Much more optimistic
the Gerson Institute, which comes to an estimated success rate (surviving five years after diagnosis) as much as 15%, with a substantial failure but 85% of cases, bankruptcy, rising to 93% for the of bowel cancer, 97% in the case of liver cancer, 99% failure rate if pancreatic cancer (749) [C. Gerson: Gerson Therapy. Macroedizioni, 2002].
dubious validity of official statistics
Official statistics of the success of the therapeutic success of current standard therapies have no basis.
In 1985, Professor. John Cairns of Harvard University published a devastating critique in Scientific American: "... apart from rare types of leukemia, can not detect any significant change in the incidence of cancer deaths as a result of large scale use of chemotherapy . There is no scientific evidence that chemotherapy can cure various types of cancer that afflict society today .... "
In 1987, 42 Members of Congress U.S. asked for clarification on alternative therapies that could be used to treat cancer. Among other things, it is noted that the surgery is not approved as a treatment for cancer, since even a study with the traditional control group was never carried out to assess the long-term results. Not even the chemotherapy is approved, but only in the experimental stage and has already lasted 50 years.
In short: Good
"Incidence Response" means only that the cancer is only reduced in volume, but does not mean it was defeated.
"Response" means: a decrease in tumor volume of the note.
"Effect Response: percentage of patients in whom we see, in the months following chemotherapy, a decrease in tumor known.
"Response Time" means how long it lasts this reduction in tumor mass.
"Complete Response" is no longer detectable in tumor diagnostic.
"Partial response: reduction in tumor size by 50%
Studies ECRI (Emergency Care Research Institute) say that the 'Incidence Response", namely the reduction of tumor mass following chemotherapy, does not correlate at all with the "prolongation of the survival of the patient's life."
"Waiver" does not mean "survive longer."
The medical literature relating to the chemotherapy he never uses words such as:
"healing" and "quality of life."
Conversely, in the medical literature on intensive chemotherapy and transplantation of bone marrow cancer with metastasis, the statistics are often published as the results appear better than they actually are.
For example, are excluded from the statistics those patients who die because of infections successor immediately after bone marrow transplantation, not caught on, and then with failure of the transplant.
These patients are defined by researchers with the term "deaths premature. "
For example, the incidence of premature death in women with metastatic breast was reported in 31 studies published from 1984 to 1994. The average was 10% in studies done from 1992 to 1994.Viceversa rises to 17% considering only those studies in 1994.
In other cases, patients died of infection are not deaths from cancer, and appear instead in the number of patients "cured".
economic cost of chemotherapy
It is believed that the chemotherapy costs to the Italian state about 30 billion Euro a year.
[The immense Balla of Cancer Research, Lorenzo Acerra, Macroedizioni, 2000, cap.8.5: The law is with the "Di Bella "]
Carcinoma of the pancreas:
The median survival time is 3 months in patients undergoing chemotherapy, while in control patients (but with free food, no special diets), not undergoing chemotherapy, time average survival is about 4 months (118) [C. Frey, Cancer, vol. 47, pp. 27-31, 1981]. By chemotherapy is reached response rates (tumor shrinkage) of more than 30% (38,285,321,401) [Scheithauer W.: Tumor Diagnostik and Therapie, vol. 5, pp. 44-48, 1984; O'Connell: Seminars in Oncol., Vol. 3, pp. 1032-1039, 1985; Meyer: Tumor Diagnostic and Therapie, vol. 8, pp. 54-58, 1987; Brennan:. In: DeVita "Cancer, Principles and practice of oncology, Lippincott and Co, Philadelphia, 4 Others edition, pp. 849-882, 1993], but the survival time, compared to patients not treated with chemotherapy (but with free food, no special diets), does not change.
lymphocytic leukemia
In this condition, in a recent Polish study conducted on 229 patients undergoing chemotherapy, median survival (50%) is about 3-4 years, with the survival curve, which stabilizes slightly in subsequent years, with survival values \u200b\u200bof 30% at 8-9 years (for patients older than 65 years) and 15-20% for patients aged less old, but adults. (1176) [T. Robak: The effect of subsequent therapies in Patients with Chronic Lymphocytic Leukemia Previously Treated Either with prednisone and cladribine or chlorambucil, Haematologica, 90, pp.: 994-996, 2005].
In another recent work lasted 10 years, 78 patients out of a total of 134 original patients were subsequently followed in the second phase of therapy, as deemed more appropriate to continue the chemo; of them, the progression-free survival of disease proved to be however, less than 3-4 years to over 75% of these 78 patients. Most of the 56 patients, who were declared fit to continue the experimental trials with these 78 patients were excluded for the following reasons: infection by viruses dell’epatite B, da Listeria monocytogenes, da Zoster virus, citopenia persistente, anemia emolitica autoimmune, neoplasia non ematologia, emorragia cerebrale, transaminasi persistentemente alte.(1177) [F.R.Mauro: Fludarabine + prednisone + alfa-interferon followed or not by alfa-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leucemia: long term results of a randomized study, Haematologica 88(12), pp.1348-1355, 2003]
Nota: secondo l’autore del presente lavoro, dott. Giuseppe Nacci, queste esclusioni dai protocolli di cura con Chemio sono molto comuni e tendono a “falsare” i risultati finali.
Leucemia linfoblastica Acuta nell’Adulto
Recent work of rescue chemotherapy for patients primarily refractory or recurrent acute lymphoblastic leukemia on 135 adults showed that survival rates tend to linearize only after the first year after chemotherapy, with survival rates below 20%. After 24 months, the percentage of patients still alive is less than about 10%. (1178) [Room A.: Gimel ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia, Haematologica, 89 (2), pp.145-155, 2004. www.haematologica.org]
Note: According to the author of this work, Dr. Giuseppe Nacci, since chemotherapy is known to be ineffective against most tumori, ci si chiede come mai la Chemio risulti essere così efficace nella Leucemia Linfoblastica Acuta. Si rammenta che molti farmaci possono erroneamente dare quadri ematologici simili alla Leucemia Linfatica Acuta, al Linfoma di Hodgkin o a quello Non Hodgkin. Ma anche la stessa risposta immunitaria del paziente contro germi o virus (es: Mononucleosi) può erroneamente condurre alla diagnosi di tumore. (Vedi dopo).
Leucemia linfatica Acuta nei bambini
La Leucemia Linfatica Acuta nei Bambini, trattata con Chemio, ha una prognosi meno pesante rispetto agli adulti. Nei bambini, infatti, studi recenti del 1998, su casistiche molto estese (2038 bambini), riferiscono percentuali di sopravvivenza variabili fra il 42% e 66.8% at 10-12 years of dstanza from chemotherapy treatment, with stabilization of the mortality curve to the fifth-sixth year of treatment with chemotherapy. (1179) [R. Consolini: Clinical relevance of CD10 expression in childhood ALL, Haematologica 83, pp.: 967-973, 1998]
Note: According to the author of this work, Dr. Giuseppe Nacci, since chemotherapy is known to be ineffective against most cancers, one wonders why the chemo appears to be so effective in acute lymphocytic leukemia. Please note that many drugs can mistakenly give blood picture similar to acute lymphocytic leukemia, lymphoma or non-Hodgkin's lymphoma. But the same patient's immune response against germs or virus (eg, mononucleosis) can lead to wrong diagnosis of cancer. (See below).
chronic myeloid leukemia are reported the following data, extrapolated to 1084 patients, all undergoing chemotherapy, and nearly all transplanted with bone marrow stem cells: relation to acute myelogenous leukemia, the median survival is better with about 60% of patients still alive at 24 months and a survival curve that tends to stabilize at slightly lower values \u200b\u200bin subsequent years. The situation differs in patients with chronic myeloid leukemia in the progressive phase, where 50% of patients are still alive after 12 months, that percentage drops to around 35% after 24 months, then stabilized around 30%. (1180) [De Souza: Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome, Haematologica, 90, pp.: 232-237, 2005. www.haematologica.org]
Acute myeloid leukemia in the elderly, in a recent study of 2004, about 621 elderly patients aged over 60 years, all undergoing chemotherapy, it appears that the median survival (50% ) is only 5-7 months. With aggressive chemotherapy, less than 10% were still alive after 20 months back, with a conservative approach (low-dose chemotherapy) after 20 months was still alive about 20% of patients, but also fell more than 10% after 20 months. Both curves decline to less than 2-5% of survivors in the months ahead. (1181) [A. Instincts: Survival of Patients with acute myeloid leukemia elderly, Haematologica, 89, pp.: 296-303, 2004; www.haematologica.org].
In another recent study of 2004 on 258 elderly patients, also suffering from acute myeloid leukemia and underwent chemotherapy with autologous stem cells, the median survival (50%) rose just 8 months and 24 months is being alive approximately 23-24% of all patients. This percentage then declines further to 36 months and 48 months (4 years), seems to finally stabilize at about 10% of survivors. (1182) [Oriol A.: Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in Patients over 60 years old. Results of the CETLAM AML-99 protocol, Haematologica, 89, pp.: 791-800, 2004; www.haematologica.org]
Myeloma
About 25% of patients survive to five years of treatment with chemotherapy Less than 5% are still alive after 10 years. (1183) [Kenneth C. Anderson: Management of Multiple Myeloma Today, Seminars in Hematology, vol. 36, No.1, suppl.3, 1999].
Hodgkin's Lymphoma
In a recent paper of 2003, were considered 97 patients, all undergoing chemotherapy, radiotherapy and stem cell transplantation, in a period of 18 years: from 1982 to 2000. In patients with chemotherapy-resistant lymphoma, median survival (50%) is only 2 years, with stabilization of the survival curve at 30% after the fifth year after treatment. In patients, however, with chemo-sensitive lymphoma, there is a slow descent of the survival curve is stable but very good for the sixth year, with percentage of survivors by 60% and remains unchanged in 10 ten years. It is believed that this curve does not tend to change further. (1184) [PL Zinzani: High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience, Haematologica, 88, (05), pp.: 522-528, 2003; www.haematologica.org ]
Nota: secondo l’autore del presente lavoro, dott. Giuseppe Nacci, poiché la Chemio è notoriamente inefficace su gran parte dei tumori, ci si chiede come mai la Chemio risulti essere così efficace nel Linfoma di Hodgkin. Si rammenta che molti farmaci possono erroneamente dare quadri ematologici simili alla Leucemia Linfatica Acuta, al Linfoma di Hodgkin o a quello Non Hodgkin. Ma anche la stessa risposta immunitaria del paziente contro germi o virus (es: Mononucleosi) può erroneamente condurre alla diagnosi di tumore. .
Linfoma NON Hodgkin
In un recente lavoro del 2005, si sono presi in considerazione 374 pazienti, tutti sottoposti a Chemio-Terapia. In base alla International Prognostic Index (IPI), were divided into four groups: low risk, low-intermediate risk, high-intermediate risk, and finally at high risk. The different survival curves obtained did not differ significantly from what is already known in the medical literature:
1) median survival (50%) about 1 year for patients at high risk, with the percentage of survivors of about 10% after fifth year, with the curve still declining in subsequent years;
2) median survival (50%) about 3 years for high-intermediate risk patients, with percentage of survivors of about 25% after the sixth year;
3) median survival (50%) about 4 years for low-intermediate risk patients, with percentage of survivors of about 40% after the sixth year, approximately 37% after the seventh year;
4) median survival (50%) about 8 years for patients at low risk, with slightly lower percentage of survivors in subsequent years. (1185) [M.van Agthoven: Cost determinants in aggressive non-Hodgkin's lymphoma, Haematologica, 90 (5), pp.: 661-672, 2005].
Note: According to the author of this work, Dr. Giuseppe Nacci, since chemotherapy is known to be ineffective against most cancers, one wonders why the chemo appears to be so effective in the NHL. Please note that certain medications can erroneously give blood picture similar to lymphocytic leukemia To acute or non-Hodgkin's lymphoma Hodgkin's lymphoma. But the same patient's immune response against bacteria or viruses (eg, mononucleosis) can lead to wrong diagnosis of cancer. It gives as an example what is written on a recent book by L. Savagno Medicine: The Non-Hodgkin's lymphomas, Piccin Editore, pp.: 202:
"... the translocation is necessary but not sufficient for neoplastic transformation of B lymphocytes The reader must agree that monoclonality is usually a sign of malignancy, but this is not an absolute rule without exceptions: in fact we have already observed at the beginning of an intense and specific immune response (defense), lymphocytes proliferate by expressing activation uniform, and only one brake that operates physiologically later makes self-limiting reactive proliferation. A clinical example is illuminating the case of RF, a young man of 28 years, that a necrotizing tonsillitis with satellite adenopathy underwent biopsy in 1984. The diagnosis of 3 different pathologists suggested a malignant lymphoma with some marginal difference in classifications between one another. One of these pathologists had also found the monoclonality of tonsillar lymphocytes. When he saw the medical oncologist, there was still - before any treatment or radiation antiblastic - a lymph node 2 cm in diameter, Gonion, while the tonsillar lesion si era spontaneamente ripianata, durante un trattamento sulfamidico. Un citoaspirato linfonodale dimostrò un tappeto omogeneo di linfoblasti atipici e spesso in mitosi, con aspetto francamente maligno. Due giorni dopo, al momento di dare la risposta, il linfonodo si era ridotto, ed aveva un diametro massimo di mezzo centimetro; si praticò allora un nuovo citoaspirato, che dimostrò che a questo punto non vi erano più i linfoblasti atipici e vivacemente proliferanti, ma a quelli si era sostituita una popolazione cellulare completamente diversa, formata quasi interamente da plasmacellule mature. Questo fatto (l’evoluzione tipica dei linfociti in blasti, che poi si trasformavano in plasmacellule) fece interpretare correttamente tutto l’episodio as a disease of inflammatory-reactive, not neoplastic is therefore desisted from any cancer treatment and the young age of responsibility is now undertaking quietly without a trace of lymphoma, more than ten years from the episode. Moral: monoclonality is a feature of almost constant in cancer, but alone is not enough for a diagnosis of complete safety ... "
Brain Cancer
The survival rate at 5 years, in the case of fourth-grade astrocytomas (glioblastoma multiforme ) is scarcely-4.5%. (1035) [McLendon R: Cancer, 98 (8), pp.: 1745-1748, 2003].
In 30 years, says the scientific paper, this value is not improved by one point.
Ovarian
101 women treated with standard dose of cisplatin showed equal survival time of 306 other women treated with high dose instead dicisplatino (22.78) [Bella M.: Abstract No. 706, in: Proc Amer. Soc Clin. Oncol., Vol.11, pp.223, 1992] [Colombo N.: Abstract No. 614, in: Proc Amer. Soc Clin. Oncology, vol. 12, pp 255, 1993].
Other studies confirm these results (81,329,330) [Conte PF: Abstract No. 880, in: Proc Amer. Soc Clin. Oncol. 12, pp 273, 1993], [Ozols RF, "Journal of Clinical Oncology, Vol 5, pp 641-647, 1987.] [Ozols RF: Seminars in Oncol., Vol. 21, Suppl. 2, pp. 1-9, 1994].
Carcinoma of the uterus and endometrium
In the case of metastases treated with different chemotherapy groups are unable to induce a partial tumor response rate of over 40%, but is not derived from randomized trials of any extension of time
survival (31,186,327,455,492,) [Williams, CJ: Raven Press, New York, pp. 417-446, 1986], [Thigpen JT: Cancer, Vol 60, pp. 2104-2116, 1987], [Hoskins WJ.in: DeVita: Cancer, Principles and practice of oncology, Lippincott and Co, Philadelphia, 4th edition, pp. 1125-1152, 1993], [Omura GA: Seminars in Oncol. Vol 21, pp. 54-62, 1994], [Bonomi P.: J.Clin.Oncol., vol.3, pp. 1079-1085, 1985].
Indeed, in a large study on 260 women with stage IIb and IV, an association of chemotherapy and radiotherapy has proved even worse than radiotherapy alone (450) [Tattersall MH: J. Clin. Oncol., Vol 13, pp. 444-445, 1995].
carcinoma of the stomach
Kingston evaluated the effectiveness of chemotherapy compared to placebo (with power still free, without special diets), in patients with inoperable gastric cancer. The group of 95 patients undergoing chemotherapy proved to have a median survival time entirely consistent with that of patients treated with placebo (221) [Kingston RD: Clinical Oncology, vol. 4, pp. 55-69, 1978].
The unanimous assessment is that many other authors of the medical literature does not show any prolongation of life through chemo-therapy, in the case of carcinoma of the stomach (178,277,300,358)
[Moertel CG.: Cancer, vol. 36, pp. 675-682, 1975], [Queiber W.: Onkologie, vol. 9, pp. 319-331, 1986], [MS Hockey: Slevin and Staquet, Raven Press, New York, pp. 221-240, 1986], [McDonald: Seminars in Oncology, vol. 15, Suppl. 3, pp. 42-49, 1988]
Twelve randomized trials, comparing the post-operative chemotherapy with control patients (but with free food, no special diets), have shown the overlap survival times (7,210,171,154).
[Alexander HL. In: DeVita: Cancer, Principles and practice of oncology, Lippincott and Co., Philadelphia, 1993, 4th ed.] [Kelsen D: Seminars in Oncol., Vol. 18, pp. 543-559, 1991], [Hermans J: J.Clin.Oncol. Vol 11, pp. 1441-1447, 1993], [Hallissey MT: The Lancet, vol. 343, pp. 1309-1312, 1994].
carcinomas of the region head / neck
Many studies show that post-operative chemotherapy does not provide any prolongation of life than patients not treated with chemotherapy, however, with free food, no special diets (60.435) [Stell PM: J. Br Cancer, vol. 61, pp. 779-787, 1990], [Chalmers T. in: De Vita: "Cancer, Principles and practice of oncology, Lippincott and Co, Philadelphia, 4th edition, pp 235-241, 1993].
Other articles show, a total of 23 studies on pre-operative chemotherapy and postoperative chemotherapy, that there is no difference between treated and untreated groups (but with free food, no special diets) . (72,74,98,195,397, 449) [Tannock IF: J. Clin. Oncol. , Vol 6, pp.1337-1387, 1984], [Clark JR: Seminars in Oncology, vol. 15, Suppl. 3, pp. 35-44, 1988], [Dodion P.: Raven Press, New York, pp. 525-547, 1986], [Choski AJ: Seminars in Oncology, vol. 15, Suppl. 3, pp. 45-49, 1998], [Schantz SP : In: De Vita V. "Cancer, Principles and practice of oncology, Lippincott and Co, Philadelphia, 4 Others edition, pp. 574-630, 1993], [Jacobs C. J. Clin. Oncol., Vol. 8 pp. 838-847, 1990]
colorectal cancer
According to Nicholls (317) [J. Nicholls: in: Slevin and Staquet, randomized studies of cancer: a critical inventory locations, Raven Press, New York, pp. 241-271, 1986] and Kane (204) [Kane MJ: Seminars in Oncology, vol. 18, pp. 421-442, 1991], the groups of patients not treated with chemotherapy (but with free food, no special diets), have demonstrated a survival greater than that of patients undergoing chemotherapy.
The results achieved on 1,523 patients, through the application of chemo-infusion therapy in liver do not demonstrate any benefit in survival and, in contrast with the actual intention of these studies even show an increase of liver metastases.
(301.429, 485) [Soybel DL: Current Problems in Cancer, vol. 11, pp. 257-356, 1987], [Weber W.: SAKK Anticancer Research, Vol 13, pp. 1839-1840, 1993], [Moertel CG. The New Engl. J. Med, vol. 330, pp. 1136-1142, 1994].
carcinoma of the lung
non-small cell lung cancer for non-small cell at an advanced stage there are no indications of an obvious influence on prognosis exercised by chemotherapy alone [U. Abel: Biomed and Pharmacother, vol. 46, 1992, update. 1995, pp. 439-452].
In the case of non-small cell bronchial carcinoma, are shown in some studies improvements in survival is not statistically significant, which are so limited that not justify the use of toxic treatments as chemotherapy.
This assessment is shared by the authors of several papers: (16,39,158,259, 296, 361) [Bakowski MT: Cancer Treatments Reviews, Vol.10, pp. 159-172, 1983], [Mitrou PS: Atemw.-Lungenkrhk., Vol. 12, pp. 544-549, 1986], [Rankin EM: Slevin and Staquet, randomized studies of cancer: a critical inventory locations, Raven Press, New York, pp. 447-492, 1986], [Liu RJ: Seminars in Oncol., Vol. 20, pp. 296-301, 1993], [Hansen: J. Clin. Oncol., Vol. 5, pp. 1711-1712, 1987]., [Browen M.: in: S. Rosenthal: "Medical support of the patient with cancer," WB Saunders Co, Philadelphia, pp. 200-215, 1987]
-small cell bronchial carcinoma
George and others, in 1986 wrote: "... with only a small percentage of remission, inability to long-term palliative action (containment of disease symptoms), and a modest number of survivors at 2-3 years apart even among the patients screened in the early stages of disease, no treatment with chemotherapy may be considered standard for the carcinoma del polmone a piccole cellule [George TK, in : Cancer, vol. 568, pp. 1193-1198, 1986].
Nel decennio successivo, Klastersky (1995) fece un riassunto dei più importanti studi che erano stati eseguiti:“…recentemente, sono stati tentati numerosi diversi regimi chemioterapici, nella speranza di migliorare i risultati aumentando l’intensità della dose.Tutti questi sforzi, dal più estremo (Chemioterapia con trapianto di midollo osseo) al più semplice (raddoppiamento delle dosi), sono falliti. Nessun risultato significativo è stato ottenuto per aumento delle dosi chemioterapiche nel trattamento del carcinoma del polmone a piccole cellule, né per combinazione di singoli agenti…”(223) [Klastersky J., in Seminars in Oncology, vol. 22, Suppl. 2, pp. 11-12, 1995].
Kokron (1982) observed: ... "in the control group not treated with chemotherapy (but with free power, without special diets, ndt), had obvious advantages for the quality of life due to an absence of side effects of chemotherapy and shorter duration of the terminal phase of illness ... "(232) [Kokron O., in: Onkologie, vol. 5, pp. 56-59, 1982].
Cancer Renal
The two-year survival after diagnosis is notoriously considered "anecdotal case" (anedoctal cases), or with survival rates very low, even at two years after diagnosis (10-20%), when subjected to chemotherapy (1174.1175) [Gattinoni L.: Renal cancer treatment: a review of the literature, Cancer, 2003, 89 (5) , pp.: 476-484; Flaningan RC.: Metastatic renal cell carcinoma, Curr. Treat. Options Oncol. 2003, 4 (5), pp.: 385-390].
prostate cancer.
On November 4, 1995, the scientific journal The Lancet announces: "... 90% of cases of prostate cancer never become significant clinically. The percentage of 10-year survival among patients who did not receive any treatment (either surgery or radiotherapy or chemotherapy or hormonal therapy) was 91.5%, compared 77% of patients undergoing radiation therapy .... " Note
author of this work, Dr. Giuseppe Nacci: Radio-therapy, as noted, it also destroys the local immune system, primarily the lymph nodes near the tumor, rich in lymphocytes, Natural Killer, unfortunately highly sensitive to radiation. Also on
The Lancet, a bolus injection Dec. 9, 1995 with the announcement-shock:
".... The total surgery for the treatment of prostate cancer fails. only to spread the disease: monitoring 14 consecutive surgical procedures, were discovered in the blood of 12 patients from the prostate cancer cells as a result of the operation. Those patients had not however revealed no tumor cells circulating in the blood before surgery. ... "Breast cancer
According to Dr. Ulica Abel, there is no direct evidence that chemotherapy prolongs survival, and this is particularly noteworthy, as all women with breast cancer undergo chemotherapy both before and after surgical treatment (Chemotherapy of advanced epithelian Cancer, Healing Journal, No.1-2, Vol 7, 1990, Gerson Institute).
Dr. Erlick Nelson, Director of ECRI (Emergency Care Research Institute), accomplished in March 1996 an in-depth analysis of published studies from the literature medical breast cancer until the year 1994. 1,500 scientific papers were studied.
Based on all available data, it appeared that:
1). In the initial phase of chemotherapy there is a "Incidence Response" higher with intensive chemotherapy and bone marrow transplantation with standard chemotherapy. That is, the tumor mass decreases ("Incidence Response"). But the "Answer" does not last long and then the cancer starts to grow.
2) The standard chemotherapy offers patients with metastatic breast cancer a "response time" longer (ie, the number of months in which the decrease tumor for a longer period), and also more patients survive for one year compared to those treated with intensive chemotherapy and Bone Marrow Transplant.
3) Scientific research on intensive chemotherapy and Bone Marrow Transplantation has not identified any subset of the population that such treatment may provide a period of non-progression of the cancer that is greater than the control group.
Until now, the medical literature has never claimed that the intensive chemotherapy and Bone Marrow Transplant may lead to recovery from breast cancer. The intensive chemotherapy and Bone Marrow Transplantation, however, involves a gain of about 150-200 thousand dollars for each Euro-transplant bone marrow. However, without considering the high percentage of deaths in the months following bone marrow transplantation, due to fatal infections from germs, which occurred in patients without, at that time, of adequate immunity, because the heavy chemotherapy performed and the lack of active bone marrow, because not yet taken root, despite the transplants performed in recent weeks. On this, it is important to point out that the Wall Street Journal, November 17, 1994, in a cover story that described the political pressure on insurance companies that would pay for bone marrow transplants in cases of breast cancer in advanced stage , the experts also provided here rapporti totalmente negativi su questo tipo di approccio.
Viceversa, a proposito invece di tumori della mammella in fase iniziale, Phillip Day, nel suo celebre libro “Cancro: se vuoi la vita prepara la verità”, alle pagine 20 e 21 riporta l’incredibile testimonianza del Dott. Irwin Bross del Roswell Memorial Park Institute di New York, testimonianza che si riporta per intero:
“Se si è una donna, alla quale è stato diagnosticato un tumore al seno in fase iniziale (cioè senza evidenza di metastasi), c’è un semplice dato scientifico che bisognerebbe conoscere: quando un patologo diagnostica una lesione del tipo “tumore al seno in stadio iniziale”, più della metà of the time the pathologist is making a mistake, that it is not really of breast cancer. What most women really, is a cancer that, given the illuminated microscope, the pathologist looks for cancer. There are possibilities that this tumor has the ability to metastasize, something that characterizes the cancer itself. The first controlled clinical trial in the world, concerning adjuvant therapy for breast cancer, was conducted in my department. Dr. Leslie Blumenson and I made a startling discovery: more than half of patients had a tumor, but they, apparently, presented themselves as rather benign. Our findings not proved popular with doctors professionals. They could not ever bear to admit the scientific truth because, at that time, treatment consisted of radical mastectomy. Admitting the truth could lead women, who had lost a breast due to an incorrect diagnosis, to take legal action for malpractice. Doctors at the National Cancer Institute, furious, we turn away from research. Probably managed to cover up our findings and to stop new publications. Essentially, the breast cancer and prostate cancer are statistically twins: when the functions of the two sexual organs diminish concerned, the cells often become abnormal and appear as tumor cells. The Journal of the American Medical Association reported surprisingly high survival values \u200b\u200bin untreated prostate cancers, which shows that 7 out of 8 tumors were NOT cancer. There is no need for women to go into panic when they heard the word "cancer." E 'panic but to make them easy victims ... "
Conclusion
Paul Wintre shows a more raw facts and explains the dynamics of the system:" It' s unlikely that any physician knowingly stop cancer treatment to protect his business or his career. But every doctor has his own ideas on the best treatment, based on what he learned. However, the Multinational Chemo-pharmaceutical companies have very strong influence on what is being taught to doctors. The doctors are too busy to investigate the statistics on cancer treatments, and assume that what they are taught at the university, or what is shown in the pages of magazines upgrade is the best treatment possible, as scientifically proven . Nor can they afford the suspicion that these treatments represent only the best for the chemo-pharmaceutical multinational, exercising their influence on cultural institutions and medical high, belonging to them ... "
(Adapted from: Paul Winter: the cancelation Home , http://www.best.com/handpen/Cancell/cancell.htm ).
Thus, supporting the view that chemotherapy is not curative and that really has little effect on the most common forms of cancer, Dr.. Martin F. Shapiro said the Los Angeles Times, January 9, 1991: "... while some oncologists inform their patients about the lack of evidence that the TERP takes effect, others may have been misled by scientific papers that express optimism without guarantees on chemotherapy. Still others are sensitive to economic incentives. Physicians can earn much more money by continuing chemotherapy practices than they can bring relief and comfort to dying patients and their families. And Dr.
. Samuel Epstein, February 4 1992, states: "... we express concern that the system generate funds for the fight against cancer, the National Cancer Institute (NCI), the American Cancer Society (ACS) and about twenty other centers for the treatment of cancer, have diverted and confused the public and Congress (U.S.) through repeated statements under which it would be to win the war on cancer ...
Table: cyto-toxic drugs for sale in Italy for chemotherapy: Alkylating agents
cyclophosphamide
ENDOXAN ASTA Asta Medica
ifosfamide
nitrogen mustard chlorambucil
:
LEUKERAN
LINFOLYSIN Glaxo Institute of New Sier. Milan
Busulfan:
MYLERAN
melphalan Glaxo: Glaxo
Alkeran
nitrosourea:
A) carmustine (BCNU)
B) Iomustina (CCNU)
diclorodiammina Cis-platinum
CIS-PLATINUM TEVA
CITOPLATINO
PLATAMINE of the Rhone Poulenc Pharmacia
cisplatin carboplatin
vials of BMS: BMS
Paraplatin of anti-tumor Antibiotics (obtained from Streptomyces):
Doxorubicin (Adriamycin):
ADRIBLASTINA Pharmacia
Daunorubicin (Daunomucina):
DAUNOBLASTINA Pharmacia
Bleomycin: Bleomycin
of Rhone Poulenc:
dactinomycin (actinomycin D):
Mitomycin C:
mitomycin C Kyowa
alkaloids of plant origin
Vinca alkaloids: Vincristine
Vinblastine Derivatives by Mandragora
VP-16 (Mandragora, Podophyllotoxin)
rate derivatives (Taxus baccatus: Tasso, Tree of Death (Italian) Taxol 100
TAXORENE
anti-metabolites (purine antagonists)
thioguanine (6 Thioguanina, 6 TG) pyrimidine antagonists
cytarabine (cytosine arabinoside, ARA-C)
Flurouracile (5-fluorouracil, 5-FU)
basal cell epitheliomas
Methotrexate (MTX)
Note: also used in rheumatoid arthritis of the adult
dacarbazine
OTHER CHEMOTHERAPEUTIC:
Vindesine Sulfate
